Given the recommendation of GLP1-RAs for the treatment of obesity and T2D in MASLD patients and the positive modulation of these agents by estrogens, which decline after menopause, a combined therapeutic approach may provide a more targeted therapeutic strategy in this subgroup. This evidence concerns the gene GLP1R and obesity disorder.